| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, Yamaguchi University School of Medicine, 1-1-1
Minamikogushi, Ube, Yamaguchi 755-8505, Japan.
2 Present address: Department of Radiology, Hiroshima Prefectural Hospital,
1-5-54, Kanda, Ujina, Minami-ku, Hiroshima 734-8530, Japan.
OBJECTIVE. The aim of this study was to evaluate the degree of hepatic enhancement and image quality in patients with cirrhosis or chronic hepatitis who underwent multiphasic contrast-enhanced dynamic imaging on MDCT at least twice using standard (300 mg I/mL) and higher (370 mg I/mL) iodine concentrations in contrast medium during follow-up periods.
MATERIALS AND METHODS. This study included 20 patients with chronic liver diseases who underwent at least two multiphasic contrast-enhanced dynamic MDCT examinations using 100 mL of standard (300 mg I/mL = group A) and higher (370 mg I/mL = group B) iodine concentrations in contrast medium. After we obtained unenhanced CT scans, we performed multiphasic scanning at 30 sec (arterial phase), 60 sec (portal phase), and 180 sec (late phase) after the start of contrast medium injection. The CT values of hepatic parenchyma, abdominal aorta, and portal vein were measured. The mean enhancement value was defined as the difference in CT values between unenhanced and contrast-enhanced images. Visual image quality was also assessed on the basis of the degree of hepatic and vascular enhancement, rated on a 4-point scale.
RESULTS. The mean hepatic parenchyma enhancement values in group B was significantly greater (p < 0.001) than those in group A during the portal phase (43.8 ± 8.2 H vs 36.2 ± 7.3 H) and the late phase (33.7 ± 7.0 H vs 27.3 ± 3.9 H), but the difference on the arterial phase images between the two groups (9.4 ± 3.2 H vs 8.3 ± 2.5 H) was not significant. The mean aorta-to-liver contrast during the arterial phase in group B was significantly higher (p < 0.001) than that in group A (236 ± 40 H vs 193 ± 32 H). For qualitative analysis, the mean visual scores for hepatic parenchyma and vasculature enhancement in group B were significantly higher than those in group A in arterial phase (p < 0.018), portal phase (p < 0.0001), and late phase (p < 0.0001).
CONCLUSION. In the same patients with chronic liver diseases, a higher iodine concentration (370 mg I/mL) in the contrast medium improves contrast enhancement of liver parenchyma in the portal phase and late phase images, improves overall image quality, and helps improve diagnostic accuracy for liver diseases on multiphasic contrast-enhanced dynamic MDCT.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Ma, A. E. Samir, N.-S. Holalkere, and D. V. Sahani Optimal Arterial Phase Imaging for Detection of Hypervascular Hepatocellular Carcinoma Determined by Continuous Image Capture on 16-MDCT Am. J. Roentgenol., September 1, 2008; 191(3): 772 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Behrendt, A. H. Mahnken, S. Stanzel, P. Seidensticker, E. Jost, R. W. Gunther, and G. Muhlenbruch Intraindividual Comparison of Contrast Media Concentrations for Combined Abdominal and Thoracic MDCT Am. J. Roentgenol., July 1, 2008; 191(1): 145 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yanaga, K. Awai, T. Nakaura, T. Namimoto, S. Oda, Y. Funama, and Y. Yamashita Optimal Contrast Dose for Depiction of Hypervascular Hepatocellular Carcinoma at Dynamic CT Using 64-MDCT Am. J. Roentgenol., April 1, 2008; 190(4): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tatsugami, M. Matsuki, G. Nakai, M. Tanikake, S. Yoshikawa, I. Narabayashi, K. Miyaji, A. Asai, S. Fujiwara, Y. Hongo, et al. Hepatic Computed Tomography for Simultaneous Depiction of Hepatocellular Carcinoma, Intrahepatic Portal Veins, and Hepatic Veins in Real-time Virtual Sonography: Initial Experience J. Ultrasound Med., August 1, 2007; 26(8): 1065 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ho, R. C. Nelson, and D. M. DeLong Determining Contrast Medium Dose and Rate on Basis of Lean Body Weight: Does This Strategy Improve Patient-to-Patient Uniformity of Hepatic Enhancement during Multi-Detector Row CT? Radiology, May 1, 2007; 243(2): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Schima, R. Hammerstingl, C. Catalano, L. Marti-Bonmati, E. J. Rummeny, F. T. Montero, A. Dirisamer, B. Westermayer, M. Bellomi, D. Brisbois, et al. Quadruple-phase MDCT of the liver in patients with suspected hepatocellular carcinoma: effect of contrast material flow rate. Am. J. Roentgenol., June 1, 2006; 186(6): 1571 - 1579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Johnson and E. K. Fishman IV Contrast Selection for MDCT: Current Thoughts and Practice Am. J. Roentgenol., February 1, 2006; 186(2): 406 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Kim, C. S. Kim, G. H. Chung, Y.-M. Han, S. Y. Lee, S. B. Chon, and J. M. Lee Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma Am. J. Roentgenol., January 1, 2006; 186(1): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Kim, H. S. Kwak, C. S. Kim, G. H. Chung, Y. M. Han, and J. M. Lee Hepatocellular Carcinoma in Patients with Chronic Liver Disease: Comparison of SPIO-enhanced MR Imaging and 16-Detector Row CT Radiology, December 21, 2005; (2005) 2381042193. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
